Clinical Trial

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Study acronym: EVOLUTION
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-12-20; most recent amendment 2025-10-08.
Status change: Not Yet Recruiting → Recruiting 2023-08-31
Trial Details
NCT Number NCT05669833
Lead Sponsor University of Pennsylvania
Collaborators: Janssen Scientific Affairs, LLC
Conditions Psoriatic Arthritis
Enrollment 63 participants
Start Date 2023-07-14
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-10-09